Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +190,916.81%
#2 Beta Finance Beta Finance +8,977.34%
#3 Velas Velas +461.19%
#4 Tribe Tribe +73.83%
#5 Orochi Network Orochi Network +51.29%
#6 Chainbase Chainbase +40.86%
#7 BabyBoomToken BabyBoomToken +34.51%
#8 Freysa AI Freysa AI +33.79%
#9 Block Street Block Street +28.93%
#10 Chrema Coin Chrema Coin +27.48%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rang in aandelen #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aandeelprijs
$0.00244926
Marktkapitalisatie
$51.67K
Verandering (1 dag)
5.88%
Verandering (1 jaar)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Categorie

Healthcare
Dividendgeschiedenis van Nuformix plc (NFX)
Nuformix plc (aandelsymbool: NFX) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Nuformix plc (NFX) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
52.00%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.00%
US
UCB SA UCB SA
UCB SA
UCB.BR
29.00%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU